⌕
Dr. Reddy's Laboratories · RDY · NYSE
Tenet 45 · Mixed
Compare
$14.79+0.61%At closeTenet 45 · Mixed
$14.79+0.09 (+0.61%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD

Dr. Reddy's Laboratories (RDY) Earnings Forecast

What Wall Street expects this business to earn, and how much analysts disagree.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

17 figures withheld by our checks. Each blank figure names its reason.

Estimates are in the company's reporting currency and are not compared to the USD share price on this page. Filed figures are in US dollars. Nothing here converts between the two.
Consensus as of Nov 16, 2026 · we check it nightly

Analysts expect Dr. Reddy's Laboratories to earn 43.90 a share in FY27 and 73.81 in FY29, growing about 30% a year. 3 analysts publish an estimate for FY27 and 1 for FY29.

Forward P/E · FY27E
Not shown
the estimate and the price are in different currencies
FY27 EPS revisions · 31 days
▲ +3.2%
42.55 to 43.90, one fiscal year at both ends
Disagreement · FY27
6.5%
high to low, 41.99 to 44.85
Coverage · FY27
3 · 18
EPS estimates · revenue estimates
Work out what the consensus implies at a multiple you chooseConsensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Are estimates going up or down lately?

The FY27 EPS consensus is 43.90, up 1.7% in 90 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 90 days. One step per nightly change.

−2.8%+1.3%+5.5%FY28 +4.4%FY27 +1.7%Aug 18Nov 16
EPS30 days90 daysshown aboveSince Jul 9
FY273 analysts▲ +3.2%42.55 to 43.90▲ +1.7%43.17 to 43.90▼ −13.9%50.96 to 43.90
FY283 analysts▲ +4.8%56.40 to 59.10▲ +4.4%56.62 to 59.10▼ −6.3%63.10 to 59.10
Dec '261 analyst▲ +2.1%11.79 to 12.04▲ +3.2%11.67 to 12.04▲ +3.2%11.67 to 12.04
Mar '271 analyst24 of 30 days−1.9% so far24 of 90 days−1.9% so far▼ −1.9%12.31 to 12.07

Contributors at both ends of the window: FY27 2 and 3. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 16, 2026 · consensus as of Nov 16, 2026

The FY28 consensus is 59.10 a share in the company's reporting currency, and a ratio carries no currency, so a multiple can still be chosen. We stop before the product: it would be a price in the reporting currency, and this share trades in US dollars.

Consensus EPS · FY28
59.10
3 analysts · low 53.09, high 66.11 · thin coverage
Multiple · five-year average P/E
19.1×
Average of the fiscal-year P/Es, FY16 to FY26. A ratio carries no currency.
×
Receipt · RDY · FY28Nov 16, 2026
Implied, a share
Not computed

We do not convert currencies here. The estimate is in the reporting currency and the share trades in US dollars, so the product would be a price in neither.

Drag the multipleShaded: where Dr. Reddy's Laboratories' P/E sat at each fiscal year end, FY16 to FY26. Each dot is one year.
5×10×15×20×25×29×
5-yr avg 19.1×10-yr median 25.2×

Each point on the line is a multiple, and the flag is the price it implies for FY28. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

Not computed across currencies. The consensus is in Dr. Reddy's Laboratories' reporting currency and the share trades in US dollars, so there is no multiple of this year's estimate to set against a growth rate.Show today's multiple against its own recordHide the multiple record
Trailing P/E at each fiscal year end, FY16 to FY26 · over 4 fiscal years. The mark is the median of the last 4.
27.1× today
0.4× low25.6× high
25.2× median
Today's mark is the trailing 27.1×, on the same basis as every year behind it. A ratio carries no currency, so the record itself is unaffected.

How much do analysts disagree?

For FY29, estimates run from 71.36 to 79.00 around an average of 73.81, drawn by 1 analyst.

FY27E3 analysts
41.99 to 44.85 · 6.5%
FY28E3 analysts
53.09 to 66.11 · 22.0%
FY29E1 analyst
71.36 to 79.00 · 10.4%

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. The last filed figure is in US dollars, so it is not placed on this axis.

Is next quarter a high bar or an easy one?

Analysts expect Dr. Reddy's Laboratories to earn 12.04 a share in the December quarter, the one estimate published. We hold no expected date for the next report.

Expected report
Not held
No expected date is published for this company's next report, so none is printed here.
Revenue expected · December quarter
91.7B
2 analysts, 90.6 to 93.2 in reporting ccy B

For the March quarter, analysts expect 12.07 a share.

Does Dr. Reddy's Laboratories usually beat or miss?

We have not been able to check a quarter yet. Our record of estimates for Dr. Reddy's Laboratories begins on Jul 9, 2026, and a quarter can be checked only when we hold an estimate for it from before the company reported.

We started recording estimates on Jul 9, 2026, so quarters that reported before that date cannot be checked.

Our record, one quarter per report
Dec '26not reported yet
Mar '27
Jun '27
Sep '27
Dec '27
Mar '28
Jun '28
Sep '28
Dec '28
Mar '29
Jun '29
Sep '29
Checked so far
None yet
one more every report
Beat expectations
Nothing to count
the first check lands after the next report
Share price reaction
Not held
there is no checked quarter to measure a reaction for
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Dr. Reddy's Laboratories on Jul 9, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.

The Street expects sales to grow 12.3% in FY28 and EPS 34.6%. Sales are part of it: the net margin moves from 10.3% to 12.3%, and the implied share count from about 833M to 833M, so these numbers assume the count stands still.Show the decomposition and the margin ladderHide the decomposition
FY28 EPS growth, in points
Revenue growth+12.3
Net margin change+22.3
Share count change0.0
EPS growth+34.6
Legs are rounded to a tenth of a point and the largest remainder carries the difference, so they add to the total. Implied shares = consensus net income ÷ consensus EPS, a direction rather than a decimal.
3 analysts publish an EPS estimate for FY27 and 18 publish revenue. Coverage thins with distance: 1 EPS estimate for FY29. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
183
FY27E
193
FY28E
91
FY29E
The FY27 panel held 2 analysts when our record of it began on Jul 9, 2026 and holds 3 tonight.

The full consensus, year by year

Consensus as of Nov 16, 2026 · filed figures as reported
Revenue · reporting ccy Bfiled · consensus average · band = low to high
Not enough estimate history to chart yet.

Coverage thins with distance: 18 revenue estimates for FY27, 9 for FY29.

Diluted EPS · reporting ccyfiled · consensus average · band = low to high
Not enough estimate history to chart yet.

Out-year bands widen as fewer analysts publish: 3 EPS estimates for FY27, 1 for FY29.

Fiscal yearRevenue reporting ccy BYoYEPS reporting ccyYoYEBITDA reporting ccy BNet inc. reporting ccy BShares BAnalysts rev · EPSFwd P/E
FY26Filed · USD3.6——————as filed27.1×
FY27E355.3352.4 to 360.2n/ca43.9041.99 to 44.85n/ca74.936.60.8318 · 3—
FY28E398.9391.1 to 410.7▲12.3%59.1053.09 to 66.11▲34.6%94.049.20.8319 · 3—
FY29E439.3428.1 to 463.0n/cb73.8171.36 to 79.00n/cb112.861.50.839 · 1—

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over that year's filed EPS, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 3 EPS estimates for FY27, 18 for revenue. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.